• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Cardiology

Meta-analysis suggests novel oral anticoagulants might be safer than warfarin for atrial fibrillation

bys25qthea
October 25, 2012
in Cardiology, Neurology, Surgery
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

Image: CC/J. Heuser

Key Study Points:

  1. The use of novel oral anticoagulants in atrial fibrillation was associated with small but statistically significant reductions in several outcomes: overall and cardiovascular mortality, stroke, systemic embolism, intracranial bleeding, and a trend towards fewer major bleeding events, in this meta-analysis of studies comparing them to vitamin K antagonists such as warfarin.

Primer: Several validated risk prediction tools such as the CHADS2 and CHA2DS2-VASc scores call for the treatment of atrial fibrillation patients at high risk for stroke or embolism with warfarin. In these patients, warfarin provides a 66% reduction in risk of stroke compared to no therapy.  However, its use has several limitations including an increased risk of life-threatening bleeding, the requirement for constant laboratory monitoring, and multiple food and drug interactions. The past decade has seen the emergence of novel oral anticoagulants (NOACs) such as dabigatran (a direct thrombin inhibitor) and rivaroxaban and apixaban (factor Xa inhibitors) which do not require frequent monitoring and have fewer interactions. Previous randomized controlled trials (RCTs) have demonstrated NOACs are non-inferior to VKAs in the treatment of atrial fibrillation.  This meta-analysis sought to reassess the comparison by harnessing the power of several randomized trials.

Background reading:

  1. Connolly SJ, Ezekowitz MD, Eikelbloom YS, et al. Dabigatran versus warfarin in patients with atrial fibrillation; N Engl J Med 2009; 361:1139.
  2. 2. Patel MR, Mahaffey KE, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation; N Engl J Med 2011; 365:883.
  3. 3. Granger CB, Alexander JH, McMurray JJV, et al. Apixaban versus warfarin in patients with atrial fibrillation; N Engl J Med 2011; 365:981.

In this [systematic review and meta-analysis] published online ahead of print in Circulation, Dentali et al pooled the results of 12 RCTs including a total of 54,875 patients. Eight studies were phase II RCTs and 4 studies were phase III RCTs. In all studies, the VKA used was warfarin.

The outcomes of the study are as follows:

NOACsWarfarinRelative Risk (95% CI)
All-cause mortality5.61%6.02%0.89 (0.83-0.96)
Cardiovascular mortality3.45%3.65%0.89 (0.82-0.98)
Stroke or systemic embolism2.40%3.13%0.77 (0.70-0.86)
Major bleeding4.90%5.54%0.86 (0.72-1.02)
Intracranial bleeding0.59%1.30%0.46 (0.39-0.56]

No difference in the rates of myocardial infarction was observed.

RELATED REPORTS

Bisphosphonates, denosumab, abaloparatide, teriparatide, and romosozumab reduce postmenopausal fracture risk

Epstein-Barr viral load monitoring reduces risk of post-liver transplant lymphoproliferative disease

Homicide deaths are on the rise for children living in the United States

In sum: This large meta-analysis suggests NOACs may provide a more efficacious, more convenient and safer alternative to warfarin in patients with atrial fibrillation.

One limitation, common to meta-analyses, is overstatement of results due to a publication bias within the literature. The asymmetric funnel plots for stroke or embolism and MI do suggest publication bias. Moreover, the size of the differences in outcomes is small, with relative risks close to 1.  This raises the question of whether these statistically significant results are truly clinically significant.

Overall, the promise of these results is tempered by the absence of a clear path to the clinic. The heterogeneity inherent in combining several agents of different classes in many populations has masked results specific to any one agent or population.  So, clinicians currently treating patients with warfarin cannot accurately infer from this study whether or not to switch a particular patient to a particular NOAC.  They must rely on their clinical judgment in applying these results.

Click to read the article in Circulation

By [MM] and [MP]

© 2012 2minutemedicine.com. All rights reserved. No works may be reproduced without written consent from 2minutemedicine.com. DISCLAIMER: Posts are not medical advice and are not intended as such. Please see a healthcare professional if you seek medical advice.

Previous Post

A molecular link between sleep deprivation and insulin resistance

Next Post

Annual seminar helps surgery residents prepare for future management roles

RelatedReports

Romosozumab significantly increases bone mineral density in postmenopausal women
Chronic Disease

Bisphosphonates, denosumab, abaloparatide, teriparatide, and romosozumab reduce postmenopausal fracture risk

January 30, 2023
Resection of colorectal liver metastases may improve cost and longevity
Chronic Disease

Epstein-Barr viral load monitoring reduces risk of post-liver transplant lymphoproliferative disease

January 30, 2023
Quick Take: State Gun Laws, Gun Ownership, and Mass Shootings in the US: Cross-Sectional Time Series
Pediatrics

Homicide deaths are on the rise for children living in the United States

January 30, 2023
Ear infections decreasing in infants
Pediatrics

High-protein supplementation improves linear growth in infants

January 30, 2023
Next Post

Annual seminar helps surgery residents prepare for future management roles

Ultrasonic dissection does not add time benefit over conventional dissection techniques in pancreatic surgery

Autologous blood transfusions lead to worse long term prognosis in colorectal cancer

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Bisphosphonates, denosumab, abaloparatide, teriparatide, and romosozumab reduce postmenopausal fracture risk
  • Epstein-Barr viral load monitoring reduces risk of post-liver transplant lymphoproliferative disease
  • Homicide deaths are on the rise for children living in the United States
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options